Real-world 10-year retrospective study of the guidelines for diagnosis and treatment of primary liver cancer in China

Table 2 Diagnosis and treatment of patients with different China Liver Cancer staging levels, n (%)

	CNLC staging
	Total (n = 3022)	Ia (n = 620)	Ιb (n = 447)	IIa (n = 60)	IIb (n = 887)	IIIa (n = 552)	IIIb (n = 362)	IV (n = 94)
HCC diagnosis
Pathology	1390 (45.9)	436 (70.3)	270 (60.4)	38 (63.3)	290 (32.6)	228 (41.3)	111 (30.6)	17 (18.1)
Imaging	1632 (54.1)	184 (29.6)	117 (39.5)	22 (36.6)	597 (67.3)	324 (58.6)	251 (69.3)	77 (81.9)
Child–Pugh grade
A	2191 (72.5)	537 (86.6)	378 (84.5)	48 (80.0)	625 (70.4)	369 (66.8)	234 (64.6)	0 (0.0)
B	737 (24.3)	83 (13.4)	69 (15.4)	12 (20.0)	262 (29.5)	183 (33.1)	128 (35.4)	0 (0.0)
C	94 (3.1)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	94 (100.0)
Treatments
LR	803 (26.5)	324 (52.2)1	188 (42.0)1	28 (46.6)1	102 (11.4)1	126 (22.8)1	35 (9.6)	0 (0.0)
RFA	203 (6.7)	104 (16.7)1	27 (6.0)1	5 (8.3)	48 (5.5)	10 (1.8)	6 (1.6)	3 (3.1)
LT	92 (3.0)	10 (1.6)1	4 (0.8)1	0 (0.0)	38 (4.2)	25 (4.5)	6 (1.6)	9 (9.5)1
TACE	1052 (34.8)	93 (15.0)	145 (32.4)1	13 (21.6)1	422 (47.5)1	210 (38.0)1	141 (38.9)1	28 (29.7)
TACE + RFA	185 (6.1)	46 (7.4)	33 (7.3)1	7 (11.6)1	67 (7.5)	11 (1.9)	15 (4.1)1	6 (6.3)
LR + RFA	89 (2.9)	23 (3.7)1	19 (4.2)	4 (6.6)1	17 (1.8)1	19 (3.4)1	5 (1.3)	2 (2.1)
Systemic anti-tumor therapy	224 (7.4)	4 (0.6)	12 (2.6)	1 (1.6)	74 (8.3)1	58 (10.5)1	63 (17.4)1	13 (13.8)1
BSC	374 (12.3)	16 (2.5)	20 (4.4)	2 (3.3)	119 (13.4)	93 (16.8)	91 (25.1)	33 (35.1)1
Adherence1	2212 (73.2)	461 (74.3)	397 (88.8)	52 (86.6)	615 (69.3)	413 (74.8)	219 (60.4)	55 (58.5)

¹Treatment modalities recommended by the Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China.

HCC: Hepatocellular carcinoma; CNLC: China Liver Cancer staging; LR: Liver resection; RFA: Radiofrequency ablation; LT: Liver transplantation; TACE: Transcatheter arterial chemoembolization; BSC: Best supportive care.